[Asia Economy Reporter Jang Hyowon] ZenenBio is showing strong performance following the news of its decision to conduct a paid-in capital increase worth 27 billion KRW.
As of 9:53 AM on the 21st, ZenenBio is trading at 2,790 KRW, up 14.81% compared to the previous day.
On this day, ZenenBio announced that it decided to conduct a third-party allotment paid-in capital increase worth 15 billion KRW targeting its largest shareholder, Genexine, and Devro DNC. Additionally, it decided on a third-party allotment paid-in capital increase worth approximately 12 billion KRW targeting JS Value Partners and RSH Group.
The funds raised through the paid-in capital increase will be used for the remaining payment for the waste treatment facility land in Gyeongsan Knowledge Industry District, construction costs for the Pyeongtaek ZenenCore Center, and operating expenses.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
